Nothing Special   »   [go: up one dir, main page]

TR200100234T2 - Biyojen estrojensülfamatların hormon sübstitüsyon terapisinde kullanılması. - Google Patents

Biyojen estrojensülfamatların hormon sübstitüsyon terapisinde kullanılması.

Info

Publication number
TR200100234T2
TR200100234T2 TR2001/00234T TR200100234T TR200100234T2 TR 200100234 T2 TR200100234 T2 TR 200100234T2 TR 2001/00234 T TR2001/00234 T TR 2001/00234T TR 200100234 T TR200100234 T TR 200100234T TR 200100234 T2 TR200100234 T2 TR 200100234T2
Authority
TR
Turkey
Prior art keywords
sulfamate
biogenic estrogen
substitution therapy
hormone substitution
sulfamates
Prior art date
Application number
TR2001/00234T
Other languages
English (en)
Inventor
Elger Walter
Lahteenmaki Pekka
Lehtinen Matti
Reddersen Gudrun
Zimmermann Holger
Oettel Michael
Schwarz Sigfrid
Original Assignee
Jenapharm Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenapharm Gmbh & Co. Kg filed Critical Jenapharm Gmbh & Co. Kg
Publication of TR200100234T2 publication Critical patent/TR200100234T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Biyojen estrojensülfamatlarin hormon substitusyon terapisinde (HRT) oral, kesintili uygulanmasinda kullanimi açiklanmaktadir. Kesintili verme 2-40 günlük araliklarla gerçeklestirilmektedir. Ek olarak gestajenlerin de, tercihen sürekli biçimde bir implantat veya intraoterin bir serbest birakma sistemi seklinde (IUD) uygulanmasi öngörülmüstür. Biyojen estrojensülfamat olarak estronsülfamat, estradiyolsülfamat, estriyolsülfamat veya asil zincirinde 7 adede kadar C atomu bulunan estronun, estradiyolün veya estriyolün N-asilsülfamati veya bu etki maddelerinden 2 veya daha fazlasinin bir kombinezonu kullanilmaktadir.
TR2001/00234T 1998-07-28 1999-05-13 Biyojen estrojensülfamatların hormon sübstitüsyon terapisinde kullanılması. TR200100234T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19834931A DE19834931A1 (de) 1998-07-28 1998-07-28 Verwendung von biogenen Estrogenen zur Hormonsubstitutionstherapie

Publications (1)

Publication Number Publication Date
TR200100234T2 true TR200100234T2 (tr) 2001-06-21

Family

ID=7876248

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/00234T TR200100234T2 (tr) 1998-07-28 1999-05-13 Biyojen estrojensülfamatların hormon sübstitüsyon terapisinde kullanılması.

Country Status (28)

Country Link
US (1) US7053077B1 (tr)
EP (1) EP1100509B1 (tr)
JP (1) JP4891479B2 (tr)
KR (1) KR20010072082A (tr)
CN (1) CN1311683A (tr)
AP (1) AP2001002054A0 (tr)
AR (1) AR016502A1 (tr)
AT (1) ATE292468T1 (tr)
AU (1) AU766019B2 (tr)
BG (1) BG105171A (tr)
BR (1) BR9912466A (tr)
CA (1) CA2338558A1 (tr)
CO (1) CO5261567A1 (tr)
DE (2) DE19834931A1 (tr)
EA (1) EA003371B1 (tr)
EE (1) EE200100053A (tr)
HK (1) HK1040192A1 (tr)
HU (1) HUP0102913A3 (tr)
IL (1) IL141081A0 (tr)
IS (1) IS5819A (tr)
MX (1) MXPA01000548A (tr)
NO (1) NO20010468L (tr)
NZ (1) NZ509521A (tr)
PL (1) PL345588A1 (tr)
SK (1) SK1292001A3 (tr)
TR (1) TR200100234T2 (tr)
WO (1) WO2000006175A1 (tr)
ZA (1) ZA200100743B (tr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1406634A1 (en) * 2001-07-13 2004-04-14 Schering Aktiengesellschaft Combination of drospirenone and an estrogen sulphamate for hrt
US8026229B2 (en) 2001-08-13 2011-09-27 Sterix Limited Antitumor-active 2-alkoxyestradiol sulfamates
US8282612B1 (en) 2008-03-07 2012-10-09 Denise H. Miller Methods and devices for intrauterine absorption
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2647379A1 (en) * 2012-04-05 2013-10-09 PregLem S.A. Combined use of a steroid sulfatase inhibitor for the treatment of endometriosis
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US9078786B1 (en) 2012-10-19 2015-07-14 Denise H. Miller Methods and devices for collecting body fluids
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
CN116392450A (zh) * 2022-09-07 2023-07-07 江苏集萃新型药物制剂技术研究所有限公司 含雌激素的皮下植入物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5314694A (en) * 1990-10-29 1994-05-24 Alza Corporation Transdermal formulations, methods and devices
WO1995001161A1 (en) * 1993-06-29 1995-01-12 Leiras Oy Pack for use in, and method of hormonal replacement therapy
DE4447715C2 (de) * 1994-08-09 1998-02-05 Jenapharm Gmbh Verwendung von Estra-1,3,5(10)-trien-Derivaten zur hormonalen Behandlung von Prostatakarzinomen
DE4429397C2 (de) * 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5(10)-trien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE4429374C1 (de) * 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
DE19610635A1 (de) * 1996-03-11 1997-09-18 Schering Ag Sequentielle Estrogen/Progesteronantagonist-Kombination für die Hormonersatz-Therapie
TW448049B (en) * 1997-03-05 2001-08-01 Akzo Nobel Nv Use of a 7Α-methyl-17Α-ethynyl-estrane derivative for the treatment of atherosclerosis
AU4957999A (en) * 1998-07-17 2000-02-07 Pharmacia & Upjohn Company Subcutaneous medroxyprogesterone acetate for contraception

Also Published As

Publication number Publication date
MXPA01000548A (es) 2002-04-08
KR20010072082A (ko) 2001-07-31
BR9912466A (pt) 2001-04-17
BG105171A (bg) 2001-07-31
ATE292468T1 (de) 2005-04-15
CA2338558A1 (en) 2000-02-10
EE200100053A (et) 2002-06-17
EA003371B1 (ru) 2003-04-24
NO20010468D0 (no) 2001-01-26
EA200100108A1 (ru) 2001-12-24
EP1100509A1 (de) 2001-05-23
WO2000006175A1 (de) 2000-02-10
IS5819A (is) 2001-01-19
JP2002521452A (ja) 2002-07-16
PL345588A1 (en) 2001-12-17
JP4891479B2 (ja) 2012-03-07
DE59911879D1 (de) 2005-05-12
IL141081A0 (en) 2002-02-10
HK1040192A1 (zh) 2002-05-31
AU5148199A (en) 2000-02-21
AU766019B2 (en) 2003-10-09
US7053077B1 (en) 2006-05-30
CO5261567A1 (es) 2003-03-31
ZA200100743B (en) 2002-05-08
HUP0102913A3 (en) 2002-03-28
CN1311683A (zh) 2001-09-05
AR016502A1 (es) 2001-07-04
NZ509521A (en) 2003-11-28
HUP0102913A2 (hu) 2002-01-28
NO20010468L (no) 2001-03-27
AP2001002054A0 (en) 2001-03-31
SK1292001A3 (en) 2001-07-10
DE19834931A1 (de) 2000-02-24
EP1100509B1 (de) 2005-04-06

Similar Documents

Publication Publication Date Title
TR200100234T2 (tr) Biyojen estrojensülfamatların hormon sübstitüsyon terapisinde kullanılması.
AR028809A1 (es) Un metodo anticonceptivo y una unidad anticonceptiva oral trifasica
UA41401C2 (uk) Фармацевтичний контрацептивний комбінований препарат
BR9709934A (pt) Kit de terapia de reposição hormonal e/ou contraceptivo uso de unidades de dosagem diária consistindo essecialmente de um progestogênio e processo de preparação de um sistema de liberação de droga
KR960704553A (ko) 적어도 하나의 프로게스토겐과 적어도 하나의 에스트로겐을 함유하는 대용요법용 제제(preparation for substitution therapy containing at least one progestogen and at least one estrogen)
RS20060348A (en) Extended use combination comprising estrogens and progestins
TR200200406T2 (tr) Kadınlara oral olmayan yollarla androjenik steroidlerin uygulanması
DK0836506T3 (da) Transdermalt plaster til indgivelse af 17-deacetyl norgestimat alene eller i kombination med et østrogen
EE200200110A (et) Etinüülöstradiooli ja drospirenooni farmatseutiline kombinatsioon kasutamiseks rasestumisvastase vahendina
HUP0300335A2 (hu) 8béta-hidrokarbil-szubsztituált ösztratriének mint szelektív hatású ösztrogének, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
UA37259C2 (uk) Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч
BR9710566A (pt) M-todo anticoncepcional monof sico e um kit compreendendo uma combina-Æo de uma progestina e estrog-nio
WO2000042942A3 (en) Buccal drug delivery system for use in male contraception
Parrott Effects of 17β-hydroxy-4-androsten-19-ol-3-one (19-hydroxytestosterone) and 5α-androstan-17β-ol-3-one (dihydrotestosterone) on aspects of sexual behaviour in castrated male rats
BR9915215A (pt) Composição farmacêutica para liberação modificada de sensibilizador de insulina
PL356847A1 (en) Hormonal composition based on a progesterone and an oestrogen and use thereof
ATE278406T1 (de) Orales contrazeptivum
UA81387C2 (en) Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
PT1007052E (pt) Combinacoes de progestinas de crescimento do endometrico e progestinas de atropia do endometrio com estrogenios, em contracepcao oral
HUP9901474A2 (hu) Szekvenciális ösztrogén/progeszteron-antagonista kombináció hormonhelyettesítő terápiához
RU97110374A (ru) Способ повышения приживляемости эмбрионов у овцематок-реципиентов введением прогестерона
RU2006126632A (ru) Стероиды, имеющие смешанный андрогенный и прогрестагенный профиль
HUP9903097A2 (hu) Progesztogén-antiprogesztogén tartalmú gyógyszerkészítmény
BR0010968A (pt) Preparação farmacêutica, embalagem farmacêutica, método de tratamento e uso de uma substância estrogenicamente ativa e substância progestogenicamente ativa na preparação de um medicamento